Table 2.
Participants of the collaborative study.
| Participant | Code | Scientist names and lab addresses |
|---|---|---|
| Amgen | A | Madeline Fort; Melissa Martin; Ruchika Jaisinghani Amgen Inc., 1120 Veterans Blvd, South San Francisco CA 94080, USA |
| Pfizer | B | Lynn O’Donnell1; Marie-Clare St. Rose 2(post-doctoral fellowship completed at Pfizer) 1. Drug Safety Research and Development, Pfizer, Inc., Groton, CT 06340, USA 2.Janssen R&D, 1400 McKean Road, Spring House, PA 19477, USA |
| Merck | C | Aarron Willingham; David Sanden; Bhagyashree Bhagwat MRL, Merck & Co., Inc., 213 E Grand Ave, South San Francisco, CA 94080, USA |
| Roche | D | Heather Hinton; Sebastian Krasniqi, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland. |
| Novartis | E | Babette Wolf Novartis Institutes for BioMedical Research, Klybeckstrasse 141, Basel, CH-4002, Switzerland |
| Janssen | F | Daniel Weinstock; Divya MekalaJanssen R&D, 1400 McKean Road, Spring House, PA 19477, USA |
| Bristol-Myers Squibb | G | Joseph Piccotti; Amber Faust; Henry Chan Bristol-Myers Squibb, 10,300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA |
| AstraZeneca | H | Richard Stebbings; Jose Carlos Chavez AstraZeneca, 121 Oyster Point Blvd, South San Francisco, CA 94080, USA |
| GSK | I | Kimberly Nadwodny; Curtis Maier; Erin Robinson GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA |
| Genentech | J | Rod Prell; Aaron Fullerton; Michael Sweeney; Karin Staflin; Genentech1 DNA Way, South San Francisco, CA 94080, USA |
| NIBSC | K | Sandrine Vessillier (Biotherapeutics); Luisa Saraiva (Biotherapeutics); Giles Sharp (Biotherapeutics); Eleanor Atkinson (TDI-Biostatistics) National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, UK |